S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
S&P 500   4,283.85 (+0.24%)
DOW   33,573.28 (+0.03%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
OTCMKTS:OXBDF

Oxford Biomedica (OXBDF) Stock Forecast, Price & News

$5.47
0.00 (0.00%)
(As of 06/6/2023 ET)
Compare
Today's Range
$5.47
▼
$5.47
50-Day Range
$5.17
▼
$5.53
52-Week Range
$3.35
▼
$6.70
Volume
7,000 shs
Average Volume
289 shs
Market Capitalization
$526.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest

OXBDF stock logo

About Oxford Biomedica (OTCMKTS:OXBDF) Stock

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Receive OXBDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

OXBDF Stock News Headlines

May 31, 2023 | americanbankingnews.com
Oxford Biomedica (OTCMKTS:OXBDF) Shares Down 0.6%
May 6, 2023 | americanbankingnews.com
Cantor Fitzgerald Begins Coverage on Oxford Biomedica (OTCMKTS:OXBDF)
June 6, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
April 30, 2023 | americanbankingnews.com
Oxford Biomedica plc Forecasted to Earn FY2023 Earnings of ($0.58) Per Share (OTCMKTS:OXBDF)
April 27, 2023 | americanbankingnews.com
Oxford Biomedica (OTCMKTS:OXBDF) Receives Buy Rating from HC Wainwright
February 20, 2023 | finance.yahoo.com
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
January 30, 2023 | finance.yahoo.com
The past year for Oxford Biomedica (LON:OXB) investors has not been profitable
November 14, 2022 | finance.yahoo.com
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
June 6, 2023 | Behind the Markets (Ad)
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
September 15, 2022 | lse.co.uk
Oxford BioMedica swings to interim loss as costs climb, revenue falls
August 19, 2022 | finance.yahoo.com
Oxford Biomedica (LON:OXB) shareholders have endured a 66% loss from investing in the stock a year ago
July 26, 2022 | lse.co.uk
Oxford BioMedica begins new project and signs license agreement
July 26, 2022 | finance.yahoo.com
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy
July 16, 2022 | finance.yahoo.com
Oxford Biomedica plc's (LON:OXB) Intrinsic Value Is Potentially 20% Below Its Share Price
July 1, 2022 | lse.co.uk
SMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca deal
July 1, 2022 | seekingalpha.com
AstraZeneca signs new three-year deal with Oxford Biomedica for COVID shot
July 1, 2022 | finance.yahoo.com
Oxford BioMedica extends Covid vaccine deal with AstraZeneca
June 14, 2022 | lse.co.uk
US FDA lifts clinical hold on Oxford BioMedica partner's trial
May 15, 2022 | finance.yahoo.com
Could The Market Be Wrong About Oxford Biomedica plc (LON:OXB) Given Its Attractive Financial Prospects?
April 20, 2022 | seekingalpha.com
Oxford Biomedica reports 63% revenue growth linked to AstraZeneca vaccine supply: Prelim
April 20, 2022 | lse.co.uk
Oxford BioMedica shares fall as warns on 2022 amid Covid jab pause
April 20, 2022 | marketwatch.com
Oxford BioMedica Sees Lower 2022 Revenue on Suspension of Covid-19 Vaccine With AstraZeneca
April 20, 2022 | ft.com
Oxford BioMedica warns revenue will be hit by AstraZeneca jab uncertainty
April 20, 2022 | uk.finance.yahoo.com
Oxford Biomedica warns on sales after pausing AstraZeneca COVID vaccine
April 20, 2022 | finance.yahoo.com
Oxford Biomedica Preliminary Results
March 13, 2022 | seekingalpha.com
Oxford Biomedica completes deal with Homology Medicines to set up 1st US subsidiary
March 10, 2022 | finance.yahoo.com
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
See More Headlines

OXBDF Price History

OXBDF Company Calendar

Today
6/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:OXBDF
Previous Symbol
NASDAQ:OXBDF
CUSIP
N/A
CIK
N/A
Web
www.oxfordbiomedica.co.uk
Phone
44-18-6578-3000
Fax
N/A
Employees
815
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$112.66 million
Price / Sales
4.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
96,260,000
Free Float
N/A
Market Cap
$526.06 million
Optionable
Not Optionable
Beta
1.11

Key Executives

  • Dr. Roch Doliveux
    Interim CEO & Chairman
  • Mr. Stuart Paynter (Age 49)
    CFO, Company Sec. & Director
    Comp: $910.2k
  • Mr. Nick Page
    Chief Operations Officer
  • Dr. James Miskin Ph.D.
    Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D.
    Chief Scientific Officer
  • Mr. Matthew Treagus
    Chief Information Officer
  • Sophia Bolhassan
    Head of Investor Relations
  • Ms. Natalie Louise Walter
    Gen. Counsel
  • Dr. Jason Slingsby MBA
    Chief Bus. & Corp. Devel. Officer
  • Ms. Sarah Macleod
    Head of Communications

Key Competitors

View All Competitors













OXBDF Stock - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OXBDF shares.
View OXBDF analyst ratings or view top-rated stocks.

How have OXBDF shares performed in 2023?

Oxford Biomedica's stock was trading at $5.22 at the beginning of 2023. Since then, OXBDF shares have increased by 4.7% and is now trading at $5.4650.
View the best growth stocks for 2023 here.

What is Oxford Biomedica's stock symbol?

Oxford Biomedica trades on the OTCMKTS under the ticker symbol "OXBDF."

How do I buy shares of Oxford Biomedica?

Shares of OXBDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oxford Biomedica's stock price today?

One share of OXBDF stock can currently be purchased for approximately $5.47.

How much money does Oxford Biomedica make?

Oxford Biomedica (OTCMKTS:OXBDF) has a market capitalization of $526.06 million and generates $112.66 million in revenue each year.

How many employees does Oxford Biomedica have?

The company employs 815 workers across the globe.

How can I contact Oxford Biomedica?

Oxford Biomedica's mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The official website for the company is www.oxfordbiomedica.co.uk. The company can be reached via phone at 44-18-6578-3000.

This page (OTCMKTS:OXBDF) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -